Asthma

Company reaches clinical milestone related to IL-9 antibody alliance

Published in Gene Therapy Weekly, September 16th, 2004

Genaera Corp. (GENR) announced achievement of a $500,000 milestone payment from MedImmune, Inc., related to the initiation of phase I clinical trials with a neutralizing interleukin-9 (IL-9) antibody.

"This is an important achievement in the development of an IL-9 neutralizing antibody product based on the identification of IL-9 as a genetic root-cause of asthma. An IL-9 neutralizing antibody is the culmination of many years of intensive genetic, immunologic, and developmental research at Genaera, the Ludwig Institute of Cancer Research, and a number of other premier academic institutions," said Roy C. Levitt, MD, president and CEO. "We believe that if this product is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry